Form 4: Elanco Animal Health Inc: CEO Jeffrey N. Simmons Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC Form 4 filing.

Summary

• On February 7, 2025, Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., acquired 240.3854 deferred stock units.
• These units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The price of the derivative security was $11.52.
• Following the transaction, Simmons directly owns 5,704.4391 deferred stock units.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of deferred stock units by the CEO can be seen as a sign of confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of deferred stock units by the CEO demonstrates confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the compensation and equity ownership of key executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals the CEO's alignment with the company's long-term success.

Key Dates

Keywords

Elanco Animal Health, Jeffrey N. Simmons, deferred stock units, SEC Form 4, executive compensation, stock match plan, insider trading